Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia
A Prospective Clinical Registry Study of Genetic Profiling and Targeted Therapies in Patients With Rare Cancers in ASIA
National Cancer Center, Japan
1,000 participants
Nov 30, 2021
OBSERVATIONAL
Conditions
Summary
This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic biomarkers by next-generation sequencing. The relationship between cancer types and prognosis, the effect of treatments, and the cancer type-specific incidence of genomic alterations will be investigated to discover more specific and effective treatment.
Eligibility
Inclusion Criteria2
- Patients with a histological diagnosis of rare cancer, cancer of unknown primary origin, or cancer of rare tissue subtypes of common cancers. (Defined in protocol.)
- Patients with Advanced stage cancer.
Exclusion Criteria1
- \. Patients with complications of cognitive impairment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Genomic sequence
Locations(18)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05217407